SABCS 2021 | Ovarian function suppression in premenopausal women with breast cancer
Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, discusses the unknown benefit of chemotherapy in premenopausal woman currently under investigation in SOFT (NCT00066690) and TEXT (NCT00066703). Dr. Regan highlights the possible requirement for younger premenopausal woman to undergo ovarian function suppression (OFS) in addition to chemotherapy due to greater risk of recurrence in comparison to woman closer to menopause. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
The SOFT and TEXT trials are coordinated by the International Breast Cancer Study Group (IBCSG), in collaboration with the Breast International Group (BIG), BIG cooperative groups, and US National Cancer Institute National Clinical Trials Network cooperative groups. Pfizer and Ipsen provided drug supply. IBCSG has received financial support for SOFT and TEXT conduct and long-term follow-up from Pfizer, Ipsen, DebioPharm, TerSera, AstraZeneca. Dr. Regan receives grant support from the Breast Cancer Research Foundation for SOFT and TEXT, and provides consulting or advisory role to Ipsen, DebioPharm, Tolmar.
